SecBot SecBot
Biotech Drug Report Generated Aug 24, 2026

Trelegy Ellipta

GSK·GSK plc
NEUTRAL
Drug Impact Rating4/10
Trial phase
Approved
Time to market
Already approved and marketed (COPD since 2017, asthma since 2020)
Why 4/10
Trelegy Ellipta is already FDA-approved and commercially marketed for both COPD (2017) and asthma (2020). There is no pending PDUFA date, Advisory Committee, or pivotal readout in the next ~12 months. The next hard catalyst is a $100M milestone payment expected in Q1 2027, which is a contractual payment, not a regulatory binary. Per the rubric, an approved drug with no pending regulatory decision scores 3-5, and GSK is a large diversified pharma where Trelegy is one of many products.
Actionable Insight NEUTRAL

Trelegy Ellipta is already approved and generating revenue, there is no near-term binary catalyst for GSK stock from this drug. Watch for Q1 2027 when a $100M milestone payment is expected from Theravance/Zymeworks, and monitor quarterly sales trends for signs of erosion from competitors like AstraZeneca's Breztri Aerosphere.

Price Chart

Loading chart...

Executive Summary

Trelegy Ellipta is GSK's once-daily single-inhaler triple therapy (ICS/LAMA/LABA) for COPD and asthma, first FDA-approved in September 2017 for COPD and expanded to asthma in September 2020. It was the first product of its kind approved in the US and is supported by robust Phase 3 data including the landmark IMPACT trial. As an already-approved, commercially established product, Trelegy generates significant revenue for GSK but offers no near-term binary catalyst. GSK is a large diversified pharma with a 'hold' analyst consensus and ~6.8% implied upside. The next notable event is a $100M milestone payment expected in Q1 2027 from the Theravance/Zymeworks transaction.

How It Works

Trelegy Ellipta is a once-daily inhaler that combines three drugs in a single device: an inhaled corticosteroid (ICS) to reduce airway inflammation, a long-acting muscarinic antagonist (LAMA) to relax airway muscles, and a long-acting beta agonist (LABA) to keep airways open. Together they treat both COPD and asthma by targeting different pathways involved in airway narrowing and inflammation.

Trial Status

Trelegy Ellipta is FDA-approved and commercially available. Pivotal Phase 3 trials (IMPACT, FULFIL) have been completed and published. Ongoing studies focus on real-world effectiveness (INTREPID) and incremental label positioning rather than new active indications.

The Two-Sided Case

▲ Bull Case4
Trelegy Ellipta was the first FDA-approved once-daily single-inhaler triple therapy for both COPD and asthma, giving it a durable first-mover advantage in a large and growing respiratory market.
The landmark Phase 3 IMPACT trial (52 weeks) showed Trelegy significantly reduced COPD exacerbations versus dual therapies (ICS/LABA and LAMA/LABA), supporting its clinical superiority narrative.
A $100 million Trelegy-related milestone payment is expected in Q1 2027 from the Theravance/Zymeworks transaction, providing a foreseeable catalyst.
GSK has a diversified pipeline beyond respiratory, and the stock trades near the low end of its 52-week range ($38.63-$61.70), with institutional accumulation from JPMorgan (doubled position) and new positions from Norges Bank and D.E. Shaw in Q2 2026.
▼ Bear Case4
Patent expirations on components could eventually open the door to generic competition, pressuring pricing and market share.
AstraZeneca's Breztri Aerosphere (budesonide/glycopyrrolate/formoterol) is a direct triple-therapy competitor that could erode Trelegy's first-mover advantage.
As an already-approved, mature product, Trelegy offers no binary upside catalyst, GSK's stock moves will be driven by the broader pipeline and commercial execution, not this single drug.
GSK's analyst consensus is 'hold' (mean recommendation 2.875) with a target mean of $58.08, implying only ~6.8% upside from the current $52.41 price.

Upcoming Catalysts

  • $100M milestone payment from Theravance/Zymeworks expected in Q1 2027
  • Quarterly sales trends and market share vs. competitors like AstraZeneca's Breztri Aerosphere

Source Filing

The SecBot filing or press-release report that triggered this drug report:

GSK plc 6-K GSK ·Originating report

Sources · 6

Hover a chip for the title
1 us.gsk.com2 drugs.com3 accessdata.fda.gov4 nejm.org5 gsk-studyregister.com6 pharmaphorum.com